Literature DB >> 25840885

Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Yun-Kai Zhang1, Yi-Jun Wang, Pranav Gupta, Zhe-Sheng Chen.   

Abstract

The ATP-binding cassette (ABC) transporters are members of a protein superfamily that are known to translocate various substrates across membranes, including metabolic products, lipids and sterols, and xenobiotic drugs. Multidrug resistance proteins (MRPs) belong to the subfamily C in the ABC transporter superfamily. MRPs have been implicated in mediating multidrug resistance by actively extruding chemotherapeutic substrates. Moreover, some MRPs are known to be essential in physiological excretory or regulatory pathways. The importance of MRPs in cancer therapy is also implied by their clinical insights. Modulating the function of MRPs to re-sensitize chemotherapeutic agents in cancer therapy shows great promise in cancer therapy; thus, multiple MRP inhibitors have been developed recently. This review article summarizes the structure, distribution, and physiological as well as pharmacological function of MRP1-MRP9 in cancer chemotherapy. Several novel modulators targeting MRPs in cancer therapy are also discussed.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25840885      PMCID： PMC4476997          DOI： 10.1208/s12248-015-9757-1

Source DB:  PubMed          Journal:  AAPS J        ISSN： 1550-7416            Impact factor:   4.009


  100 in total

1.  Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12.

Authors:  H Yabuuchi; H Shimizu; S Takayanagi; T Ishikawa
Journal:  Biochem Biophys Res Commun       Date:  2001-11-09       Impact factor: 3.575

2.  Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11.

Authors:  Ikuko Ota; Aki Sakurai; Yu Toyoda; Satoshi Morita; Takeshi Sasaki; Takashi Chishima; Minoru Yamakado; Yuki Kawai; Takefumi Ishidao; Alexander Lezhava; Koh-Ichiro Yoshiura; Shinji Togo; Yoshihide Hayashizaki; Takashi Ishikawa; Toshihisa Ishikawa; Itaru Endo; Hiroshi Shimada
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

3.  Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).

Authors:  Martin G Belinsky; Zhe-Sheng Chen; Irina Shchaveleva; Hao Zeng; Gary D Kruh
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

4.  Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Authors:  Elizabeth A Hopper-Borge; Timothy Churchill; Chelsy Paulose; Emmanuelle Nicolas; Joely D Jacobs; Olivia Ngo; Yehong Kuang; Alex Grinberg; Heiner Westphal; Zhe-Sheng Chen; Andres J Klein-Szanto; Martin G Belinsky; Gary D Kruh
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

5.  Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane.

Authors:  J König; D Rost; Y Cui; D Keppler
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

6.  The role of the efflux carriers Abcg2 and Abcc2 for the hepatobiliary elimination of benzo[a]pyrene and its metabolites in mice.

Authors:  Jasmin Kranz; Stefanie Hessel; Julia Aretz; Albrecht Seidel; Ernst Petzinger; Joachim Geyer; Alfonso Lampen
Journal:  Chem Biol Interact       Date:  2014-10-16       Impact factor: 5.192

7.  Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat.

Authors:  Maciej J Zamek-Gliszczynski; Keith A Hoffmaster; Joan E Humphreys; Xianbin Tian; Ken-Ichi Nezasa; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2006-07-20       Impact factor: 4.030

8.  Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver.

Authors:  C J Soroka; J M Lee; F Azzaroli; J L Boyer
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

9.  Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1).

Authors:  Marianne K DeGorter; Gwenaëlle Conseil; Roger G Deeley; Robert L Campbell; Susan P C Cole
Journal:  Biochem Biophys Res Commun       Date:  2007-10-31       Impact factor: 3.575

10.  Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.

Authors:  Naomi Walsh; Annemarie Larkin; Susan Kennedy; Lisa Connolly; Jo Ballot; Wei Ooi; Giuseppe Gullo; John Crown; Martin Clynes; Lorraine O'Driscoll
Journal:  BMC Urol       Date:  2009-06-24       Impact factor: 2.264
View more
  65 in total

1.  Efficacy of traditional Chinese medicine in treating cancer.

Authors:  Jiao Nie; Changlin Zhao; L I Deng; Jia Chen; Bin Yu; Xianlin Wu; Peng Pang; Xiaoyin Chen
Journal:  Biomed Rep       Date:  2015-11-05

2.  Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Zi-Ning Lei; Guan-Nan Zhang; Xiao-Yu Zhang; De-Shen Wang; Sweilem B Al-Rihani; Suneet Shukla; Suresh V Ambudkar; Amal Kaddoumi; Zhi Shi; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2018-10-28       Impact factor: 8.679

3.  GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance.

Authors:  Pranav Gupta; Meina Xie; Silpa Narayanan; Yi-Jun Wang; Xiu-Qi Wang; Timothy Yuan; Ziyue Wang; Dong-Hua Yang; Zhe-Sheng Chen
Journal:  J Cell Biochem       Date:  2017-05-03       Impact factor: 4.429

4.  Molecular and structural characteristics of multidrug resistance-associated protein 7 in Chinese liver fluke Clonorchis sinensis.

Authors:  Fuhong Dai; Won Gi Yoo; Ji-Yun Lee; Yanyan Lu; Jhang Ho Pak; Woon-Mok Sohn; Sung-Jong Hong
Journal:  Parasitol Res       Date:  2017-01-05       Impact factor: 2.289

5.  Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells.

Authors:  Ekaterina A Potter; Evgenia V Dolgova; Anastasia S Proskurina; Yaroslav R Efremov; Alexandra M Minkevich; Aleksey S Rozanov; Sergey E Peltek; Valeriy P Nikolin; Nelly A Popova; Igor A Seledtsov; Vladimir V Molodtsov; Evgeniy L Zavyalov; Oleg S Taranov; Sergey I Baiborodin; Alexander A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Oncotarget       Date:  2017-02-07

6.  Inhibition of P-glycoprotein stimulates cell death under Hypoxia-mimicking conditions.

Authors:  A S Vdovin; P V Maximchik; A V Kulikov; B D Zhivotovsky; V G Gogvadze
Journal:  Dokl Biochem Biophys       Date:  2017-04-19       Impact factor: 0.788

7.  Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.

Authors:  Mikko Gynther; Ilaria Proietti Silvestri; Jacob C Hansen; Kasper B Hansen; Tarja Malm; Yevheniia Ishchenko; Younes Larsen; Liwei Han; Silke Kayser; Seppo Auriola; Aleksanteri Petsalo; Birgitte Nielsen; Darryl S Pickering; Lennart Bunch
Journal:  J Med Chem       Date:  2017-12-05       Impact factor: 7.446

8.  Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma.

Authors:  Yuan-Yuan Guo; Yuan Wu; Xiao-Wei Jia; Wei An
Journal:  Lab Invest       Date:  2017-08-21       Impact factor: 5.662

9.  Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.

Authors:  Guan-Nan Zhang; Yun-Kai Zhang; Yi-Jun Wang; Anna Maria Barbuti; Xi-Jun Zhu; Xin-Yue Yu; Ai-Wen Wen; John N D Wurpel; Zhe-Sheng Chen
Journal:  Pharmacol Res       Date:  2017-01-25       Impact factor: 7.658

10.  Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy.

Authors:  Jingsheng Yuan; Zhijie Yin; Kaixiong Tao; Guobing Wang; Jinbo Gao
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.